Assessing chest pain patients presenting to the emergency area (EA) is still a clinical challenge, as acute myocardial infarction (AMI) diagnosis is not adjudicated in the majority of patients. New generation high sensitivity troponin assays (hs-cTn) still present some limitations, thus, novel biomarkers to early rule-in and rule- out myocardial infarction in chest pain patients presenting to the EA are sought after. Among all, heart- type fatty acid binding protein (h-FABP) has been largely investigated. Studies performed on HFABP in these patients present marked heterogeneity. However, it can be stated that HFABP is clearly not a reliable marker for AMI diagnosis, neither as a stand-alone test nor in combination with hs- cTn. More interventional trials are needed and more homogeneous studies are required to understand whether HFABP can add incremental value in rule- out AMI and risk stratify chest pain patients, however, available data may not encourage going on investigating.

Giulia Bivona, L.A. (2018). Clinical utility of HFABP in myocardial infarction. ACTA MEDICA MEDITERRANEA [10.19193/0393-6384_2018_6_250].

Clinical utility of HFABP in myocardial infarction

Giulia Bivona;Luisa Agnello;Daniela Butera;Marcello Ciaccio
2018-01-01

Abstract

Assessing chest pain patients presenting to the emergency area (EA) is still a clinical challenge, as acute myocardial infarction (AMI) diagnosis is not adjudicated in the majority of patients. New generation high sensitivity troponin assays (hs-cTn) still present some limitations, thus, novel biomarkers to early rule-in and rule- out myocardial infarction in chest pain patients presenting to the EA are sought after. Among all, heart- type fatty acid binding protein (h-FABP) has been largely investigated. Studies performed on HFABP in these patients present marked heterogeneity. However, it can be stated that HFABP is clearly not a reliable marker for AMI diagnosis, neither as a stand-alone test nor in combination with hs- cTn. More interventional trials are needed and more homogeneous studies are required to understand whether HFABP can add incremental value in rule- out AMI and risk stratify chest pain patients, however, available data may not encourage going on investigating.
2018
Giulia Bivona, L.A. (2018). Clinical utility of HFABP in myocardial infarction. ACTA MEDICA MEDITERRANEA [10.19193/0393-6384_2018_6_250].
File in questo prodotto:
File Dimensione Formato  
Clinical-utility-of-HFABP-in-acute-myocardial-infarction2018Acta-Medica-MediterraneaOpen-Access.pdf

accesso aperto

Dimensione 110.42 kB
Formato Adobe PDF
110.42 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/347219
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact